STMN2

Across TCGA pan-cancer cohorts, STMN2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated STMN2 data layer compared with 16 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher STMN2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated STMN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC are the cancer types where STMN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.597	0.258	.005	32	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

STMN2–PDAC (OS)

Open the PDAC breakdown →